Takeru Funakoshi

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Koji Kurose, Yoshihiro Ohue, Hisashi Wada et al. · Clinical Cancer Research · 2015 · 254 citations

Medicine, Immunology, Oncology +16

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

Yoshio Nakamura, Shigehisa Kitano, Akira Takahashi et al. · Oncotarget · 2016 · 160 citations · Full text

Medicine, Immunology, Oncology +17

Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients

Yasuhiro Nakamura, Kenjiro Namikawa, Kenji Yoshino et al. · Annals of Oncology · 2020 · 140 citations

Medicine, Clinical Sciences, Oncology +17

Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 101 citations

Medicine, Immunology, Oncology +16

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Oncotarget · 2018 · 90 citations · Full text

Medicine, Dermatology, Oncology +17